These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38160175)
1. Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody. Wang Z; Wang D; Chen J; Gao F; Jiang Y; Yang C; Qian C; Chi X; Zhang S; Xu Y; Lu Y; Shen J; Zhang C; Li J; Zhou L; Li T; Zheng Q; Yu H; Li S; Xia N; Gu Y Sci Bull (Beijing); 2024 Feb; 69(4):512-525. PubMed ID: 38160175 [TBL] [Abstract][Full Text] [Related]
2. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310 [TBL] [Abstract][Full Text] [Related]
3. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli]. Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683 [TBL] [Abstract][Full Text] [Related]
4. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196 [TBL] [Abstract][Full Text] [Related]
5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
7. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Schellenbacher C; Roden R; Kirnbauer R J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991 [TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Ahmed AI; Bissett SL; Beddows S Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024 [TBL] [Abstract][Full Text] [Related]
9. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. Ludmerer SW; Benincasa D; Mark GE J Virol; 1996 Jul; 70(7):4791-4. PubMed ID: 8676509 [TBL] [Abstract][Full Text] [Related]
10. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490 [TBL] [Abstract][Full Text] [Related]
12. Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. Liu X; Chen J; Wang Z; Wang D; He M; Qian C; Song S; Chi X; Kong Z; Zheng Q; Wang Y; Yu H; Zhao Q; Zhang J; Li S; Gu Y; Xia N Emerg Microbes Infect; 2019; 8(1):1721-1733. PubMed ID: 31769733 [TBL] [Abstract][Full Text] [Related]
13. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339 [TBL] [Abstract][Full Text] [Related]
14. Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. Yaegashi N; Jenison SA; Batra M; Galloway DA J Virol; 1992 Apr; 66(4):2008-19. PubMed ID: 1312618 [TBL] [Abstract][Full Text] [Related]
15. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies. Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682 [TBL] [Abstract][Full Text] [Related]
16. Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum. Yu Y; Guo J; Li D; Liu Y; Yu Y; Wang L Vaccine; 2018 Aug; 36(32 Pt B):4927-4934. PubMed ID: 30037483 [TBL] [Abstract][Full Text] [Related]
17. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766 [TBL] [Abstract][Full Text] [Related]
18. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748 [TBL] [Abstract][Full Text] [Related]
19. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912 [TBL] [Abstract][Full Text] [Related]
20. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. Orozco JJ; Carter JJ; Koutsky LA; Galloway DA J Virol; 2005 Aug; 79(15):9503-14. PubMed ID: 16014913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]